Key statistics
As of last trade, Pharvaris NV (9EN:FRA) traded at 20.20, 47.45% above the 52 week low of 13.70 set on Aug 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.50 |
---|---|
High | 20.60 |
Low | 19.30 |
Bid | 20.60 |
Offer | 21.80 |
Previous close | 19.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.01m |
Free float | 32.66m |
P/E (TTM) | -- |
Market cap | 1.14bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 18:55 GMT.
More ▼
- Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
- Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
- Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
- Pharvaris to Host Virtual Investor Event on October 23, 2024
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
- Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
- Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
- Pharvaris Presents Data at the Bradykinin Symposium 2024
- Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
More ▼